Prevention of Seasonal Affective Disorder - Tabular View

Tracking Information
First Received Date ^ICMJE	September 30, 2002
Last Updated Date	June 23, 2005
Start Date ^ICMJE
Primary Completion Date
Current Primary Outcome Measures ^ICMJE
Original Primary Outcome Measures ^ICMJE
Change History	Complete list of historical versions of study NCT00046449 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE
Original Secondary Outcome Measures ^ICMJE

Descriptive Information
Brief Title ^ICMJE	Prevention of Seasonal Affective Disorder
Official Title ^ICMJE
Brief Summary	A Placebo Controlled Study Evaluating The Effectivess Of Medication In Preventing Seasonal Affective Disorder
Detailed Description
Study Phase	Phase III
Study Type ^ICMJE	Interventional
Study Design ^ICMJE	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Condition ^ICMJE	Seasonal Affective Disorder (SAD)
Intervention ^ICMJE	Drug: Investigational Seasonal Affective Disorder (SAD) Drug
Study Arms / Comparison Groups
Publications *
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE
Completion Date
Primary Completion Date
Eligibility Criteria ^ICMJE	Inclusion Criteria: (Patient must meet these criteria in order to be eligible for this study.) Patient has a history of Major Depressive Disorder (MDD) with a seasonal pattern. Exclusion Criteria: (Patient cannot meet these criteria in order to be eligible for this study.) Patient has a current or past history of seizure disorder or brain injury. Patient has a history or current diagnosis of anorexia nervousa or bulimia. Patient has recurrent summer depression more frequently than winter depression. Patient has primary diagnosis of panic disorder, Obsessive Compulsive Disorder (OCD), Posttraumatic Stress Disorder (PTSD), acute distress disorder, bipolar II disorder or other psychotic disorders. Patient has initiated psychotherapy within the last 3 months.
Gender	Both
Ages	18 Years and older
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	United States, Canada

Administrative Information
NCT ID ^ICMJE	NCT00046449
Responsible Party
Study ID Numbers ^ICMJE	398149
Study Sponsor ^ICMJE	GlaxoSmithKline
Collaborators ^ICMJE
Investigators ^ICMJE
Information Provided By	GlaxoSmithKline
Verification Date	July 2004
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP